A randomised phase II study comparing the clinical response and toxicity of Carboplatin plus pegylated Liposomal Doxorubicin (CLD) vs Carboplatin plus Paclitaxel (CP) in potentially platinum sensitive ovarian cancer patients

Hellenic Cooperative Oncology Group0 个研究点目标入组 201 人开始时间: 2009年6月11日最近更新: 2020年1月13日

适应症

试验速览

暂无简介。

•Women at least 18 years old, with histologically confirmed recurrent ovarian cancer (OC), 6 months or more after platinum-based chemotherapy, patients with bidimensionally measurable disease or only elevated serum tumour marker CA125 (more than twice the upper limit of normal), with Eastern Cooperative Oncology Group (ECOG) performance status 0–2 and life expectancy of at least 3 months were eligible. Adequate bone marrow, hepatic and renal functions were required.

•Patients with a history of malignancy other than completely excised in situ carcinoma of the cervix or basal carcinoma of the skin, prior or recurrent central nervous system metastases, serious cardiac disease, other serious medical illness or inability to comply with the treatment plan and follow-up visits were excluded. Also patients with residual neurotoxicity from previous platinum and/or taxane chemotherapy were excluded.

发起方

Hellenic Cooperative Oncology Group